

Table 1A: Prior month HCT vs. current EPO dose, 2003
HD patients only

Current month EPO dose	HCT in prior month			
	≤33	>33 and ≤36	>36	Total
Number of patient months				
Less Than 2,001 Units per Session	177,597	146,847	303,462	627,906
2,001 - 12,000 Units per Session	437,231	503,422	599,602	1,540,255
More Than 12,000 Units per Session	172,834	72,414	54,114	299,362
Total	787,662	722,683	957,178	2,467,523
Percent of total				
Less Than 2,001 Units per Session	7%	6%	12%	25%
2,001 - 12,000 Units per Session	18%	20%	24%	62%
More Than 12,000 Units per Session	7%	3%	2%	12%
Total	32%	29%	39%	100%
Percent of row				
Less Than 2,001 Units per Session	28%	23%	48%	100%
2,001 - 12,000 Units per Session	28%	33%	39%	100%
More Than 12,000 Units per Session	58%	24%	18%	100%
Total	32%	29%	39%	100%
Percent of column				
Less Than 2,001 Units per Session	23%	20%	32%	25%
2,001 - 12,000 Units per Session	56%	70%	63%	62%
More Than 12,000 Units per Session	22%	10%	6%	12%
Total	100%	100%	100%	100%

Relation of Hct to EPO dose




Table 1B: Partial range of possible values for EPO dose-response variable
Units of EPO per session per g/dL of hemoglobin

Dose	Hct / Hg							
	Hct=24	Hct=27	Hct=30	Hct=33	Hct=36	Hct=39	Hct=42	Hct=45
	Hb=8g/dL	Hb=9g/dL	Hb=10g/dL	Hb=11g/dL	Hb=12g/dL	Hb=13g/dL	Hb=14g/dL	Hb=15g/dL
1k units	125	111	100	91	83	77	71	67
2k units	250	222	200	182	167	154	143	133
3k units	375	333	300	273	250	231	214	200
4k units	500	444	400	364	333	308	286	267
5k units	625	556	500	455	417	385	357	333
6k units	750	667	600	545	500	462	429	400
7k units	875	778	700	636	583	538	500	467
8k units	1,000	889	800	727	667	615	571	533
9k units	1,125	1,000	900	818	750	692	643	600
10k units	1,250	1,111	1,000	909	833	769	714	667
11k units	1,375	1,222	1,100	1,000	917	846	786	733
12k units	1,500	1,333	1,200	1,091	1,000	923	857	800
13k units	1,625	1,444	1,300	1,182	1,083	1,000	929	867
14k units	1,750	1,556	1,400	1,273	1,167	1,077	1,000	933
15k units	1,875	1,667	1,500	1,364	1,250	1,154	1,071	1,000
16k units	2,000	1,778	1,600	1,455	1,333	1,231	1,143	1,067
17k units	2,125	1,889	1,700	1,545	1,417	1,308	1,214	1,133
18k units	2,250	2,000	1,800	1,636	1,500	1,385	1,286	1,200
19k units	2,375	2,111	1,900	1,727	1,583	1,462	1,357	1,267
20k units	2,500	2,222	2,000	1,818	1,667	1,538	1,429	1,333
21k units	2,625	2,333	2,100	1,909	1,750	1,615	1,500	1,400
22k units	2,750	2,444	2,200	2,000	1,833	1,692	1,571	1,467
23k units	2,875	2,556	2,300	2,091	1,917	1,769	1,643	1,533
24k units	3,000	2,667	2,400	2,182	2,000	1,846	1,714	1,600




Table 1B: Partial range of possible values for EPO dose-response variable
Units of EPO per session per g/dL of hemoglobin





Table 2A: Alternative Models 1 - 5
Bundle 1C payment per session
HD Patients, 2003 (N=1,943,552 months)*

	Model				
	Model 1	Model 2	Model 3	Model 4	Model 5
Model form	Log	Log	Log	Log	Log
Base CM model	X	X	X	X	X
Prior EPO Response (1 to 3 months)**		X		X	X
Prior EPO Response (6 to 8 months)**			X		
Hct (prior month)				X	
Facility					X
Patient months	1,943,552	1,943,552	1,943,552	1,943,552	1,943,552
Percent of total used in analysis	79%	79%	79%	79%	79%
R-squared	0.0743	0.7588	0.2795	0.8874	0.8175
Mean (Actual)	\$101.37	\$101.37	\$101.37	\$101.37	\$101.37
Std. Dev. Predicted	\$22.24	\$71.08	\$43.14	\$76.87	\$73.78
Std. Dev. Actual	\$81.60	\$81.60	\$81.60	\$81.60	\$81.60
Correlation with prior month prediction error					
t-1	0.73	0.49	0.66	0.51	0.47
t-2	0.62	0.29	0.49	0.37	0.25
t-3	0.57	0.20	0.38	0.29	0.16
t-4	0.53	0.22	0.29	0.28	0.18
t-5	0.50	0.23	0.21	0.27	0.18
t-6	0.48	0.21	0.12	0.26	0.17
t-7	0.45	0.19	0.08	0.23	0.15
t-8	0.43	0.18	0.08	0.22	0.14
t-9	0.42	0.18	0.13	0.22	0.14
t-10	0.40	0.16	0.13	0.20	0.13
t-11	0.38	0.15	0.12	0.18	0.11
Percentile distribution of prediction error***					
Std Dev	\$77.73	\$65.18	\$71.65	\$66.51	\$63.53
Minimum	-\$300.63	-\$734.71	-\$771.75	-\$1,105.94	-\$1,184.01
1st	-\$82.08	-\$161.84	-\$107.81	-\$178.25	-\$162.92
5th	-\$56.66	-\$55.93	-\$56.96	-\$55.15	-\$55.42
25th	-\$24.44	-\$16.44	-\$21.08	-\$15.70	-\$15.88
50th	\$4.46	\$6.68	\$5.45	\$6.74	\$5.99
75th	\$46.18	\$35.63	\$42.27	\$34.43	\$33.37
95th	\$152.52	\$97.07	\$130.95	\$92.53	\$91.42
99th	\$288.68	\$181.33	\$244.15	\$176.01	\$168.61
Maximum	\$6,929.15	\$6,927.98	\$6,911.27	\$6,939.45	\$6,879.61

Notes

* See Note 1.

** See Note 2.

*** See Note 3.

Table 2B: Models 1 - 5: Independent Variable Coefficients
Bundle 1C payment per session
HD Patients, 2003 (N=1,943,552 months)*

	Freq.**	Multiplier								
		Model 1	Model 2	Model 3	Model 4	Model 5				
Model parameters										
Model form		Log	Log	Log	Log	Log				
Base CM model		X	X	X	X	X				
EPO Response (1 to 3 months)			X		X	X				
EPO Response (6 to 8 months)				X						
Hct (prior month)					X					
Facility									X	
Independent Variables										
Prior EPO dose-response Hematocrit (prior month)			1.396		1.287		1.374 0.967		1.384	
Age group										
<18 years	0.11%	0.841	0.936	11%	0.950	13%	0.915	9%	1.196	42%
18-44	11.62%	1.014	1.002	-1%	1.025	1%	0.997	-2%	1.002	-1%
45-59	22.68%	1.020	0.998	-2%	1.016	0%	0.997	-2%	0.997	-2%
60-69	23.78%	1.035	1.010	-2%	1.020	-1%	1.009	-3%	1.009	-3%
70-79 (ref)	27.54%	1.000	1.000		1.000		1.000		1.000	
80+	14.26%	0.955	0.983	3%	0.974	2%	0.983	3%	0.980	3%
Female	47.53%	1.178	1.063	-10%	1.074	-9%	1.062	-10%	1.066	-10%
Female & age 18-44	4.67%	1.149	1.027	-11%	1.046	-9%	1.026	-11%	1.030	-10%
Race										
White (ref)	54.96%	1.000	1.000		1.000		1.000		1.000	
Native American	1.43%	0.975	0.969	-1%	0.962	-1%	0.982	1%	1.008	3%
Asian	2.38%	1.005	0.983	-2%	0.979	-3%	0.979	-3%	0.987	-2%
Black	36.96%	1.055	1.130	7%	1.138	8%	1.131	7%	1.100	4%
Pacific Islander	0.84%	0.880	0.928	5%	0.918	4%	0.927	5%	0.993	13%
Other	3.30%	1.004	1.000	0%	1.000	0%	1.006	0%	1.016	1%
Unknown	0.13%	1.022	1.086	6%	1.081	6%	1.085	6%	1.011	-1%

Table 2B: Models 1 - 5: Independent Variable Coefficients
Bundle 1C payment per session
HD Patients, 2003 (N=1,943,552 months)*

	Freq.**	Multiplier								
		Model 1	Model 2		Model 3		Model 4		Model 5	
Model parameters										
Model form		Log	Log		Log		Log		Log	
Base CM model		X	X		X		X		X	
EPO Response (1 to 3 months)			X				X		X	
EPO Response (6 to 8 months)					X					
Hct (prior month)							X			
Facility									X	
Hispanic										
No (ref)	13.14%	1.000	1.000		1.000		1.000		1.000	
Yes	0.35%	0.908	0.995	10%	0.980	8%	0.996	10%	1.001	10%
Unknown		1.069	1.040	-3%	1.049	-2%	1.039	-3%	1.016	-5%
Duration of RRT										
Starting month	1.14%	1.138	1.576	39%	1.546	36%	1.592	40%	1.589	40%
Month 1	1.66%	1.456	1.205	-17%	1.269	-13%	1.149	-21%	1.212	-17%
Month 2	1.84%	1.656	1.173	-29%	1.348	-19%	1.118	-33%	1.177	-29%
Month 3	2.24%	1.472	1.093	-26%	1.228	-17%	1.099	-25%	1.097	-25%
Month 4	2.11%	1.294	1.007	-22%	1.116	-14%	1.046	-19%	1.010	-22%
Month 5	2.13%	1.231	1.001	-19%	1.059	-14%	1.045	-15%	1.004	-18%
Month 6	2.00%	1.203	1.021	-15%	0.985	-18%	1.053	-12%	1.023	-15%
Month 7	2.02%	1.163	1.025	-12%	0.939	-19%	1.048	-10%	1.025	-12%
Month 8	1.93%	1.102	1.000	-9%	0.909	-17%	1.021	-7%	1.001	-9%
Month 9	1.87%	1.071	0.991	-7%	0.896	-16%	1.011	-6%	0.991	-7%
Months 10-12	5.52%	1.045	0.995	-5%	0.930	-11%	1.007	-4%	0.994	-5%
Year 2	19.02%	1.006	0.986	-2%	0.966	-4%	0.988	-2%	0.983	-2%
Year 3	15.28%	0.996	0.991	0%	0.985	-1%	0.991	0%	0.989	-1%
Year 4+ (ref)	41.26%	1.000	1.000		1.000		1.000		1.000	

Table 2B: Models 1 - 5: Independent Variable Coefficients
Bundle 1C payment per session
HD Patients, 2003 (N=1,943,552 months)*

	Freq.**	Multiplier									
		Model 1	Model 2	Model 3	Model 4	Model 5					
Model parameters											
Model form		Log	Log	Log	Log	Log					
Base CM model		X	X	X	X	X					
EPO Response (1 to 3 months)			X		X	X					
EPO Response (6 to 8 months)				X							
Hct (prior month)					X						
Facility						X					
Body size measures											
Body surface area		1.033	1.012	-2%	1.018	-1%	1.012	-2%	1.014	-2%	
Body mass index											
<18.5	4.36%	0.983	0.988	0%	0.990	1%	0.986	0%	0.992	1%	
≥18.5 (ref)		1.000	1.000		1.000		1.000		1.000		
Laboratory values											
Hematocrit at start of RRT		0.979	0.995	2%	0.992	1%	0.996	2%	0.995	2%	
Behavioral measures											
Inability to ambulate	2.60%	1.051	1.007	-4%	1.018	-3%	1.006	-4%	1.017	-3%	
Inability to transfer	0.74%	0.955	0.959	0%	0.957	0%	0.956	0%	0.970	2%	
Tobacco use	5.31%	0.933	0.978	5%	0.972	4%	0.978	5%	0.988	6%	
Alcohol Dependence	4.23%	1.050	1.004	-4%	1.017	-3%	1.004	-4%	1.000	-5%	
Drug Dependence	1.79%	1.116	1.020	-9%	1.041	-7%	1.021	-8%	1.025	-8%	
Comorbid Conditions											
Congestive Heart Failure	28.12%	1.039	1.001	-4%	0.998	-4%	1.005	-3%	1.001	-4%	
Ischemic Heart Disease	25.71%	0.994	0.999	1%	0.997	0%	1.001	1%	0.998	0%	
Peripheral Vascular Disease	26.71%	1.030	1.005	-2%	1.004	-3%	1.010	-2%	1.003	-3%	
Cardiac Dysrhythmias	20.79%	1.044	1.006	-4%	1.010	-3%	1.008	-3%	1.006	-4%	
Cerebrovascular Disease	19.00%	1.055	1.012	-4%	1.018	-4%	1.015	-4%	1.008	-4%	
COPD	17.86%	1.050	1.011	-4%	1.020	-3%	1.012	-4%	1.011	-4%	
Diabetes (1° or Contributing)	17.13%	0.989	0.999	1%	1.000	1%	0.999	1%	1.002	1%	
Cardiac Arrest	1.58%	1.107	1.021	-8%	1.053	-5%	1.015	-8%	1.020	-8%	
Pericarditis	1.23%	1.198	1.018	-15%	1.062	-11%	1.016	-15%	1.010	-16%	

Table 2B: Models 1 - 5: Independent Variable Coefficients
Bundle 1C payment per session
HD Patients, 2003 (N=1,943,552 months)*

	Freq.**	Multiplier								
		Model 1	Model 2	Model 3	Model 4	Model 5				
Model parameters										
Model form		Log	Log	Log	Log	Log				
Base CM model		X	X	X	X	X				
EPO Response (1 to 3 months)			X			X			X	
EPO Response (6 to 8 months)				X						
Hct (prior month)					X					
Facility									X	
Other infections	20.31%	1.057	1.012	-4%	1.035	-2%	1.012	-4%	1.013	-4%
Septicemia/Shock	12.44%	1.164	1.025	-12%	1.088	-7%	1.024	-12%	1.029	-12%
Other Hepatitis	12.27%	0.951	0.993	4%	0.987	4%	0.994	4%	0.998	5%
Hepatitis B	3.09%	1.027	1.021	-1%	1.022	0%	1.019	-1%	0.998	-3%
AIDS	1.25%	0.995	1.001	1%	1.011	2%	0.997	0%	1.023	3%
Aspir. & Bact. Pneumonias	1.99%	1.128	1.003	-11%	1.070	-5%	0.999	-11%	1.003	-11%
Major respiratory disease	1.28%	1.161	1.022	-12%	1.084	-7%	1.019	-12%	1.020	-12%
HIV Positive Status	0.97%	1.153	1.024	-11%	1.048	-9%	1.020	-12%	1.019	-12%
Opportunistic Infections	0.67%	1.206	1.014	-16%	1.099	-9%	1.005	-17%	1.019	-15%
GI Ulcer - no hemorrhage	3.13%	1.132	1.030	-9%	1.072	-5%	1.028	-9%	1.030	-9%
Hereditary Hemolytic Anemias	2.11%	1.107	0.991	-11%	1.020	-8%	0.984	-11%	1.003	-9%
GI Tract Bleeding	1.99%	1.265	1.044	-18%	1.139	-10%	1.037	-18%	1.044	-18%
Acquired Hemolytic Anemias	1.42%	1.087	0.997	-8%	1.023	-6%	0.993	-9%	1.017	-6%
Sickle-Cell Anemia	0.37%	1.226	1.011	-18%	1.054	-14%	1.000	-18%	1.017	-17%
Esophageal Varices	0.19%	1.367	1.019	-25%	1.129	-17%	0.997	-27%	1.034	-24%
Other Anemias	0.00%	2.703	1.257	-53%	1.446	-47%	1.259	-53%	1.284	-53%
Breast & Other Cancers	5.81%	1.099	1.036	-6%	1.055	-4%	1.034	-6%	1.031	-6%
Metastatic Cancers	1.09%	1.142	1.024	-10%	1.063	-7%	1.019	-11%	1.023	-10%
Lung & Severe Cancers	1.02%	1.122	1.022	-9%	1.056	-6%	1.016	-9%	1.018	-9%
Lymphoma	0.56%	1.172	1.043	-11%	1.076	-8%	1.039	-11%	1.041	-11%
Multiple Myeloma	0.51%	1.188	1.025	-14%	1.082	-9%	1.018	-14%	1.020	-14%
Leukemia	0.43%	1.176	1.014	-14%	1.081	-8%	1.004	-15%	1.022	-13%
Lymphatic & Major Cancers	0.04%	1.095	1.033	-6%	1.032	-6%	1.036	-5%	1.028	-6%

Table 2B: Models 1 - 5: Independent Variable Coefficients
Bundle 1C payment per session
HD Patients, 2003 (N=1,943,552 months)*

		Multiplier									
	Freq.**	Model 1		Model 2		Model 3		Model 4		Model 5	
Model parameters											
Model form		Log	Log		Log		Log		Log		
Base CM model		X	X		X		X		X		X
EPO Response (1 to 3 months)			X				X		X		X
EPO Response (6 to 8 months)					X						
Hct (prior month)							X				
Facility										X	
Hyperparathyroidism	13.50%	1.008	1.010	0%	1.010	0%	1.012	0%	1.022	1%	
Myelodysplastic Syndrome	1.17%	1.377	1.047	-24%	1.136	-17%	1.034	-25%	1.045	-24%	
Monoclonal Gammopathy	0.66%	1.090	1.011	-7%	1.042	-4%	1.009	-7%	1.014	-7%	
Myelofibrosis	0.03%	1.215	1.107	-9%	1.163	-4%	1.099	-10%	1.117	-8%	
Prior health care utilization											
Prior month hospitalization	17.27%	1.560	1.207	-23%	1.311	-16%	1.148	-26%	1.205	-23%	
Notes											
* See Note 1.											
** See Note 4.											

Table 3A: Case Mix Models 6 to 13
Bundle 1C payment per session
HD Patients, 2003 (N=1,943,552 months)*

	Model							
	Model 6	Model 7	Model 8	Model 9	Model 10	Model 11	Model 12	Model 13
Model form	Log	Log	Log	Log	Log	Log	Log	Linear
Reduced base CM model	X			X	X	X	X	X
Vintage	X		X	X	X	X	X	X
Prior EPO Response (1 to 3 months)**								
Prior EPO Response (6 to 8 months)**		X	X	X	X	X	X	X
Hct (prior month)					X		X	
Facility						X	X	
Patient months	1,944,012	1,944,012	1,944,012	1,944,012	1,944,012	1,944,012	1,944,012	1,944,012
Percent of total used in analysis	79%	79%	79%	79%	79%	79%	79%	79%
R-squared	0.0690	0.2420	0.2416	0.2790	0.3703	0.3349	0.4564	0.2494
Mean (Actual)	\$101.37	\$101.37	\$101.37	\$101.37	\$101.37	\$101.37	\$101.37	\$101.37
Std. Dev. Predicted	\$21.43	\$40.14	\$40.10	\$43.10	\$49.65	\$47.22	\$55.12	\$40.75
Std. Dev. Actual	\$81.59	\$81.59	\$81.59	\$81.59	\$81.59	\$81.59	\$81.59	\$81.59
Correlation with prior month prediction error								
t-1	0.73	0.68	0.68	0.66	0.64	0.63	0.60	0.65
t-2	0.63	0.51	0.51	0.49	0.50	0.46	0.45	0.49
t-3	0.57	0.39	0.39	0.38	0.39	0.34	0.33	0.38
t-4	0.53	0.29	0.30	0.29	0.29	0.25	0.23	0.30
t-5	0.51	0.20	0.21	0.21	0.22	0.16	0.16	0.22
t-6	0.49	0.10	0.11	0.12	0.14	0.07	0.08	0.13
t-7	0.46	0.06	0.07	0.08	0.11	0.03	0.06	0.09
t-8	0.44	0.06	0.08	0.08	0.12	0.04	0.07	0.09
t-9	0.43	0.11	0.12	0.13	0.15	0.08	0.11	0.14
t-10	0.41	0.12	0.13	0.13	0.15	0.08	0.10	0.14
t-11	0.39	0.12	0.13	0.13	0.14	0.08	0.10	0.14

Table 3A: Case Mix Models 6 to 13
Bundle 1C payment per session
HD Patients, 2003 (N=1,943,552 months)*

	Model							
	Model 6	Model 7	Model 8	Model 9	Model 10	Model 11	Model 12	Model 13
Model form	Log	Log	Log	Log	Log	Log	Log	Linear
Reduced base CM model	X			X	X	X	X	X
Vintage	X		X	X	X	X	X	X
Prior EPO Response (1 to 3 months)**								
Prior EPO Response (6 to 8 months)**		X	X	X	X	X	X	X
Hct (prior month)					X		X	
Facility						X	X	
Percentile distribution of prediction error***								
Std Dev	\$78.13	\$74.04	\$73.24	\$71.75	\$69.74	\$69.42	\$67.25	\$70.69
Minimum	-\$325.32	-\$384.95	-\$381.38	-\$775.15	-\$1,258.67	-\$900.92	-\$2,385.48	-\$335.44
1st	-\$80.89	-\$106.62	-\$104.38	-\$108.01	-\$109.39	-\$110.96	-\$114.39	-\$122.00
5th	-\$56.31	-\$56.23	-\$56.51	-\$56.89	-\$55.95	-\$56.90	-\$55.90	-\$79.65
25th	-\$24.71	-\$22.44	-\$21.93	-\$21.13	-\$20.19	-\$20.36	-\$19.15	-\$37.32
50th	\$4.30	\$5.45	\$5.55	\$5.41	\$5.51	\$4.61	\$4.74	-\$10.49
75th	\$46.42	\$45.15	\$44.18	\$42.33	\$40.20	\$39.48	\$36.89	\$24.52
95th	\$153.84	\$138.64	\$136.90	\$131.22	\$122.77	\$124.52	\$114.10	\$111.06
99th	\$290.89	\$253.08	\$251.73	\$244.63	\$230.96	\$232.12	\$215.37	\$225.99
Maximum	\$6,933.93	\$6,912.76	\$6,914.19	\$6,915.36	\$6,933.36	\$6,814.10	\$6,848.64	\$6,884.72

Notes

* See Note 1.

** See Note 2.

*** See Note 3.

Table 3B: Models 6 - 13: Independent Variable Coefficients
Bundle 1C payment per session
HD Patients, 2003 (N=1,943,552 months)*

		Multiplier							
	Freq.**	Model 6	Model 7	Model 8	Model 9	Model 10	Model 11	Model 12	Model 13
Model parameters									
Model form		Log	Log	Log	Log	Log	Log	Log	Linear
Reduced base CM model		X			X	X	X	X	X
Vintage		X		X	X	X	X	X	X
EPO Response (1 to 3 months)									
EPO Response (6 to 8 months)			X	X	X	X	X	X	X
Hct (prior month)							X	X	
Facility								X	X
Independent Variables									
Prior EPO dose-response Hematocrit (prior month)			1.328	1.330	1.292	1.279 0.956	1.274	1.258 0.951	1.309
Socio-demographic									
Age <18	0.11%	0.971			0.940	0.911	1.213	1.183	1.079
Female	47.53%	1.118			1.081	1.078	1.085	1.082	1.043
Black	36.96%	1.182			1.151	1.149	1.105	1.102	1.108
Pacific Islander	0.84%	0.915			0.928	0.925	0.998	1.000	0.940
Duration of RRT									
Starting month	1.14%	1.595		1.566	1.549	1.567	1.564	1.584	1.565
Month 1	1.66%	1.274		1.472	1.271	1.186	1.279	1.181	1.157
Month 2	1.84%	1.383		1.413	1.359	1.261	1.359	1.248	1.219
Month 3	2.24%	1.273		1.231	1.240	1.238	1.243	1.239	1.159
Month 4	2.11%	1.156		1.121	1.127	1.176	1.129	1.184	1.078
Month 5	2.13%	1.098		1.066	1.071	1.129	1.074	1.139	1.030
Month 6	2.00%	1.080		0.984	0.996	1.037	1.002	1.049	0.941
Month 7	2.02%	1.061		0.931	0.949	0.980	0.955	0.991	0.893
Month 8	1.93%	1.023		0.901	0.920	0.949	0.926	0.960	0.874
Month 9	1.87%	0.999		0.889	0.906	0.934	0.912	0.944	0.860
Months 10-12	5.52%	0.983		0.927	0.942	0.959	0.944	0.965	0.913

Table 3B: Models 6 - 13: Independent Variable Coefficients
Bundle 1C payment per session
HD Patients, 2003 (N=1,943,552 months)*

		Multiplier							
	Freq. **	Model 6	Model 7	Model 8	Model 9	Model 10	Model 11	Model 12	Model 13
Model parameters									
Model form		Log	Log	Log	Log	Log	Log	Log	Linear
Reduced base CM model		X			X	X	X	X	X
Vintage		X		X	X	X	X	X	X
EPO Response (1 to 3 months)									
EPO Response (6 to 8 months)			X	X	X	X	X	X	X
Hct (prior month)							X	X	
Facility								X	X
Laboratory values									
Hematocrit at start of RRT		0.986			0.992	0.993	0.991	0.993	0.993
Body size measures***									
Body surface area		1.391			1.221	1.212	1.241	1.229	1.187
Body mass index < 18.5		1.005			0.995	0.991	1.000	0.996	1.011
Comorbid Conditions****									
Cardiac Arrest	1.58%	1.133			1.065	1.057	1.062	1.054	1.079
Pericarditis	1.23%	1.184			1.072	1.065	1.066	1.058	1.087
Septicemia/Shock	12.44%	1.149			1.101	1.095	1.103	1.098	1.100
Aspir. & Bact. Pneumonias	1.99%	1.108			1.077	1.068	1.073	1.062	1.095
Major respiratory disease	1.28%	1.135			1.089	1.081	1.086	1.077	1.088
Opportunistic Infections	0.67%	1.200			1.115	1.093	1.119	1.096	1.155
GI Ulcer - no hemorrhage	3.13%	1.111			1.076	1.071	1.076	1.071	1.074
GI Tract Bleeding	1.99%	1.187			1.138	1.122	1.134	1.115	1.141
Sickle-Cell Anemia	0.37%	1.214			1.063	1.040	1.078	1.052	1.117
Esophageal Varices	0.19%	1.297			1.137	1.093	1.155	1.106	1.196

Table 3B: Models 6 - 13: Independent Variable Coefficients
Bundle 1C payment per session
HD Patients, 2003 (N=1,943,552 months)*

		Multiplier								
	Freq. **	Model 6	Model 7	Model 8	Model 9	Model 10	Model 11	Model 12	Model 13	
Model parameters										
Model form		Log	Log	Log	Log	Log	Log	Log	Linear	
Reduced base CM model		X			X	X	X	X	X	
Vintage		X		X	X	X	X	X	X	
EPO Response (1 to 3 months)										
EPO Response (6 to 8 months)			X	X	X	X	X	X	X	
Hct (prior month)						X		X		
Facility							X	X		
Breast & Other Cancers	5.81%	1.079			1.055	1.053	1.049	1.046	1.044	
Metastatic Cancers	1.09%	1.131			1.068	1.057	1.066	1.055	1.088	
Lung & Severe Cancers	1.02%	1.111			1.060	1.051	1.056	1.046	1.077	
Lymphoma	0.56%	1.160			1.082	1.071	1.082	1.071	1.103	
Multiple Myeloma	0.51%	1.166			1.091	1.077	1.087	1.071	1.129	
Leukemia	0.43%	1.159			1.085	1.064	1.095	1.071	1.142	
Myelodysplastic Syndrome	1.17%	1.291			1.133	1.105	1.131	1.098	1.165	
Myelofibrosis	0.03%	1.263			1.186	1.173	1.200	1.189	1.226	
Prior health care utilization										
Prior month hospitalization	17.27%	1.387			1.320	1.227	1.312	1.207	1.276	
Notes										
* See Note 1.										
** See Note 4.										
*** See Note 5.										
**** See Note 6.										

Notes

- Note 1. Includes patient months with 1-20 Medicare hemodialysis-equivalent dialysis sessions. Excludes patient months with missing data for one or more patient characteristics.
- Note 2. EPO response measures were calculated as the average EPO divided by the average HCT over a three month period ending 1-3 or 6-8 months prior to the current record.
- Note 3. These columns show the percent of patient months having prediction errors that are less than or equal to the dollar amount shown.
- Note 4. From May case mix models. Provided as a rough indicator of prevalence.
- Note 5. Body surface area (DuBois): per 0.1 m²
Body mass index (kg/m²)
- Note 6. The more specific description of selected comorbid conditions is as follows:
- Cardiac Arrest within 12 months
 - Pericarditis within 12 months
 - Septicemia/Shock within 6 months
 - Aspir. & Bact. Pneumonias: aspiration and specified bacterial pneumonias within 6 months
 - Major respiratory disease: pneumococcal pneumonia, emphysema, lung abscess within 6 months
 - Opportunistic Infections within 6 months
 - GI Ulcer - no hemorrhage within 6 months
 - GI Tract Bleeding within 6 months
 - Sickle-Cell Anemia from 1999 to present
 - Esophageal Varices within 6 months
 - Breast & Other Cancers: Breast, prostate, colorectal and other cancers within 12 months
 - Metastatic Cancers within 12 months
 - Lung & Severe Cancers: lung, upper digestive tract, and other severe cancers within 12 months
 - Lymphoma within 2 years
 - Multiple Myeloma within 12 months
 - Leukemia within 12 months
 - Myelodysplastic Syndrome from 1999 to present
 - Myelofibrosis within 12 months